About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker TEVA · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 12, 2026A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or C…
NCT05668013 · Crohn Disease, Colitis, Ulcerative
TEV-48574 Dose Regimen A, TEV-48574 Dose Regiment B
TEVA
Teva Branded Pharmaceutical Products R&D LLC
Phase 2Active, not recruiting247Jan 5, 2026Registry ↗
Nov 5, 2026Two Trials to Evaluate TEV-53408 in Participants With Non-Segmental Vitiligo
NCT07920211 · Vitiligo
TEV-53408 Dose A, TEV-53408 Dose B
TEVA
Teva Branded Pharmaceutical Products R&D LLC
Phase 2/3Not yet recruiting1,020Sep 12, 2030Registry ↗
Nov 5, 2026A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
NCT06568237 · Multiple System Atrophy
TEV-56286, Placebo
TEVA
Teva Branded Pharmaceutical Products R&D LLC
Phase 2Active, not recruiting349Sep 15, 2027Registry ↗
Nov 4, 2026A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propiona…
NCT06664619 · Asthma
Fp/ABS, FP
TEVA
Teva Branded Pharmaceutical Products R&D LLC
Phase 3Completed
was active, not recruiting
649Oct 26, 2026Registry ↗
Nov 4, 2026A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effectiv…
NCT06052267 · Asthma
TEV-56248, Albuterol sulfate
TEVA
Teva Branded Pharmaceutical Products R&D LLC
Phase 3Active, not recruiting2,769Dec 31, 2026Registry ↗
Nov 3, 2026Real-World Impact of TV-44749 in Adults With Schizophrenia
NCT07913100 · Schizophrenia
TV-44749
TEVA
Teva Branded Pharmaceutical Products R&D LLC
—Not yet recruiting1,085May 31, 2031Registry ↗
Oct 29, 2026A Trial to Test the Safety and Efficacy of TEV-53408 in Participants With Vitiligo
NCT06625177 · Vitiligo
TEV-53408
TEVA
Teva Branded Pharmaceutical Products R&D LLC
Phase 1Recruiting66Apr 26, 2028Registry ↗
Oct 9, 2026An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
NCT07197866 · Multiple System Atrophy
TEV-56286
TEVA
Teva Branded Pharmaceutical Products R&D LLC
Phase 2Recruiting200May 3, 2029Registry ↗
Oct 9, 2026A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease
NCT06807463 · Celiac Disease
TEV-53408, Placebo
TEVA
Teva Branded Pharmaceutical Products R&D LLC
Phase 2Active, not recruiting50Oct 2, 2026Registry ↗
Oct 1, 2026A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis
NCT04729621 · Osteoporosis, Postmenopausal
TVB-009, Prolia®
TEVA
Teva Pharmaceuticals USA
Phase 3Completed332Dec 31, 2022Registry ↗
Sep 30, 2026Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The…
NCT05617820 · Dyspareunia
Estradiol, Imvexxy
TEVA
Teva Pharmaceuticals USA
Phase 3Completed1,050Mar 15, 2024Registry ↗
Sep 8, 2026A Trial to Assess TEV-56286 at Different Doses in Healthy Participants
NCT07674940 · Healthy Volunteers
TEV-56286, Placebo
TEVA
Teva Branded Pharmaceutical Products R&D LLC
Phase 1Recruiting69Jan 15, 2027Registry ↗
Aug 27, 2026Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Participants With Huntingt…
NCT07601516 · Huntington's Disease, Chorea
Deutetrabenazine
TEVA
Teva Branded Pharmaceutical Products R&D LLC
Phase 4Completed50Oct 24, 2025Registry ↗
Aug 7, 2026Mass Balance Clinical Trial With TEV-56286
NCT06627231 · Healthy Participants
TEV-56286, [14C]-TEV-56286
TEVA
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1Completed8Nov 29, 2024Registry ↗
Aug 4, 2026Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination W…
NCT06290102 · Asthma
TEV-56248, Fp MDPI
TEVA
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1Completed30Oct 1, 2024Registry ↗
Jul 27, 2026Fremanezumab Managed Access Program for Pediatric Patients
NCT03539393 · Migraine
Fremanezumab
TEVA
Teva Branded Pharmaceutical Products R&D LLC
—Available——Registry ↗
Jul 24, 2026A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
NCT04530110 · Migraine
Fremanezumab
TEVA
Teva Branded Pharmaceutical Products R&D LLC
Phase 3Completed499Aug 15, 2025Registry ↗
Jun 30, 2026Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia
NCT06253546 · Schizophrenia
TV-44749 318mg, Oral Olanzapine 10mg/day
TEVA
Teva Branded Pharmaceutical Products R&D LLC
Phase 1Completed24Jun 12, 2025Registry ↗
Jun 22, 2026A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Ye…
NCT04458857 · Migraine
Fremanezumab, Placebo
TEVA
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 3Completed235Mar 13, 2024Registry ↗
Jun 4, 2026An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV…
NCT06480552 · Advanced Solid Tumors
TEV-56278, Pembrolizumab
TEVA
Teva Branded Pharmaceutical Products R&D LLC
Phase 1Recruiting240May 26, 2029Registry ↗
Mar 27, 2026A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
NCT05499130 · Crohn Disease, Colitis, Ulcerative
TEV-48574, Placebo
TEVA
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2Completed290Nov 12, 2024Registry ↗
Mar 19, 2026A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler W…
NCT03890666 · Asthma
Albuterol eMDPI DS, albuterol
TEVA
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 4Completed333Oct 4, 2021Registry ↗
Mar 17, 2026A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to…
NCT05693935 · Schizophrenia
TV-44749, Placebo
TEVA
Teva Branded Pharmaceutical Products R&D LLC
Phase 3Completed675Mar 19, 2024Registry ↗
Feb 9, 2026A Study to Assess New Formulations of TEV-56286
NCT06911567 · Healthy Participants
TEV-56286 Test, TEV-56286 Reference
TEVA
Teva Branded Pharmaceutical Products R&D LLC
Phase 1Completed47May 22, 2025Registry ↗
Jan 30, 2026A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple My…
NCT05590377 · Multiple Myeloma
Modakafusp Alfa, Daratumumab
TEVA
Teva Branded Pharmaceutical Products R&D LLC
Phase 1/2Terminated15May 22, 2024Registry ↗
Jan 29, 2026A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
NCT05556616 · Multiple Myeloma
Modakafusp alfa, Lenalidomide
TEVA
Teva Branded Pharmaceutical Products R&D LLC
Phase 1Terminated15Jun 4, 2024Registry ↗
Jan 29, 2026A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With…
NCT04157517 · Neoplasms, Melanoma
Modakafusp Alfa, Pembrolizumab
TEVA
Teva Branded Pharmaceutical Products R&D LLC
Phase 1/2Terminated45Dec 20, 2023Registry ↗
Jan 29, 2026A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT03215030 · Multiple Myeloma
Modakafusp alfa, Dexamethasone
TEVA
Teva Branded Pharmaceutical Products R&D LLC
Phase 1/2Terminated272Jul 1, 2024Registry ↗
Jan 26, 2026Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Particip…
NCT06319170 · Schizophrenia, Schizoaffective Disorder
Olanzapine Extended Release, Olanzapine Immediate Release
TEVA
Teva Branded Pharmaceutical Products R&D LLC
Phase 1Completed106Jan 15, 2025Registry ↗
Jan 14, 2026An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Par…
NCT06315283 · Schizophrenia
TV-44749, Oral olanzapine
TEVA
Teva Branded Pharmaceutical Products R&D LLC
Phase 1Completed153Aug 14, 2025Registry ↗
Jan 14, 2026A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combina…
NCT04392648 · Relapsed and/or Refractory Multiple Myeloma
TAK-573, Pomalidomide
TEVA
Teva Branded Pharmaceutical Products R&D LLC
Phase 1Withdrawn0Nov 10, 2023Registry ↗
Dec 19, 2025A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17…
NCT04464707 · Migraine
Fremanezumab, Placebo
TEVA
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 3Completed292Nov 29, 2024Registry ↗
Dec 17, 2025Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psori…
NCT06742957 · Plaque Type Psorisis
Tapinarof Cream 1%, VTAMA®
TEVA
Teva Pharmaceuticals USA
Phase 3Completed560Oct 7, 2025Registry ↗
Nov 26, 2025A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safe…
NCT05458011 · Migraine
Fremanezumab, Placebo
TEVA
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 3Completed365Jan 31, 2024Registry ↗
Oct 7, 2025Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic I…
NCT04976192 · Chronic Urticaria
TEV-45779, XOLAIR® Injection
TEVA
Teva Pharmaceuticals USA
Phase 3Completed608Apr 5, 2024Registry ↗
Sep 26, 2024Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment O…
NCT05550337 · Acne Vulgaris
Trifarotene 0.005 % Topical Cream, AKLIEF®
TEVA
Teva Pharmaceuticals USA
Phase 3Completed807May 9, 2023Registry ↗
Sep 19, 2024Topiramate 25 mg Capsules Under Fasting Conditions
NCT00905164 · Healthy
Topiramate Capsules, 25 mg, Topamax® Capsules, 25 mg
TEVA
Teva Pharmaceuticals USA
Phase 1Completed24Jun 2002Registry ↗
Sep 19, 2024Topiramate 25 mg Capsules Under Fed Conditions
NCT00904943 · Healthy
Topiramate Capsules, 25 mg, Topamax® Capsules, 25 mg
TEVA
Teva Pharmaceuticals USA
Phase 1Completed18Jul 2002Registry ↗
Sep 19, 2024Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fasting Conditions
NCT00834977 · Healthy
Amlodipine-benazepril 10 mg-20 mg capsules, Lotrel® 10 mg-2…
TEVA
Teva Pharmaceuticals USA
Phase 1Completed48May 2004Registry ↗
Sep 19, 2024Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Fasting Conditions
NCT00829426 · Healthy
Alprazolam Extended-Release 3 mg Tablets, Alprazolam Extend…
TEVA
Teva Pharmaceuticals USA
Phase 1Completed32Jun 2005Registry ↗
Aug 21, 2024Valacyclovir 1000 mg Tablet Under Fed Conditions
NCT01149460 · Healthy
Valacyclovir, Valacyclovir
TEVA
Teva Pharmaceuticals USA
Phase 1Completed36Sep 2004Registry ↗
Aug 21, 2024Ondansetron HCl Orally Disintegrating Tablets Under Non-Fasting Conditions
NCT00934921 · Healthy
Ondansetron, Zofran®
TEVA
Teva Pharmaceuticals USA
Phase 1Completed24Feb 2003Registry ↗
Aug 21, 2024Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions
NCT00934180 · Healthy
Ondansetron, Zofran®
TEVA
Teva Pharmaceuticals USA
Phase 1Completed24Dec 2002Registry ↗
Aug 21, 2024Amoxicillin-Clavulanic Acid 400 Mg-57 mg Chewable Tablets Under Non-Fasting Conditions
NCT00836901 · Healthy
amoxicillin-clavulanic acid, Augmentin®
TEVA
Teva Pharmaceuticals USA
Phase 1Completed52Sep 2003Registry ↗
Aug 21, 2024Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fed Conditions
NCT00835367 · Healthy
Amlodipine-benazepril 10 mg-20 mg capsules, Lotrel® 10 mg-2…
TEVA
Teva Pharmaceuticals USA
Phase 1Completed68Mar 2004Registry ↗
Aug 21, 2024Zolpidem Tartrate 10 mg Tablets Under Fasting Conditions
NCT00833521 · Healthy
Zolpidem 10 mg tablets, AMBIEN® 10 mg tablets
TEVA
Teva Pharmaceuticals USA
Phase 1Completed38Feb 2002Registry ↗
Aug 21, 2024Zaleplon 10mg Capsules Under Fasting Conditions
NCT00829998 · Healthy
Zaleplon 10 mg Capsules, Sonata® 10 mg Capsules
TEVA
Teva Pharmaceuticals USA
Phase 1Completed40Feb 2004Registry ↗
Aug 21, 2024Zaleplon 10 mg Capsules Under Non-Fasting Conditions
NCT00829868 · Healthy
Zaleplon 10 mg Capsules, SONATA® 10 mg capsules
TEVA
Teva Pharmaceuticals USA
Phase 1Completed42Mar 2004Registry ↗
Aug 20, 2024Tamsulosin Hydrochloride 0.4 mg Capsules Under Fed Conditions
NCT01149733 · Healthy
Tamsulosin, Tamsulosin
TEVA
Teva Pharmaceuticals USA
Phase 1Completed32Nov 2004Registry ↗
Aug 20, 2024Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Non-Fasting Cond…
NCT01149473 · Healthy
Losartan potassium/Hydrochlorothiazide, Losartan potassium/…
TEVA
Teva Pharmaceuticals USA
Phase 1Completed80Apr 2004Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 10:39 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances